Insulet’s (PODD) robust execution to expand the Omnipod 5 platform globally is a tailwind. The company is also capitalizing on the significant growth opportunities in the Type 2 diabetes space. PODD carries a Zacks Rank #2 (Buy) currently.Factors Driving PODD StockInsulet is making significant strides in its key strategic imperatives to help patients manage diabetes efficiently.  The company’s first strategy revolves around increasing access and awareness of Omnipod products. In the second quarter of 2024, ...

SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today is sharing progress on its development of the BioJet™ Oral Delivery Platform, which is designed to replace injection with needle-free, oral delivery, at the 14th Annual Partnership in Drug Delivery (PODD) meeting in Boston, Massachusetts. "We have now demonstrated the ability to autonomously deliver to the small intestine in canine models with our smaller, 00-size ...

Insulet Corporation (PODD) is driving share gains with its prime Omnipod 5 AID (automated insulin delivery) system, which is highly promising for growth in the upcoming quarters. The company continues to expand the platform to new countries with sensor integrations. A strong solvency position also bodes well for the stock. However, the mounting costs of Omnipod 5 production, coupled with its excessive reliance on this offering, raise concerns for the company.In the past year, this Zacks Rank #2 (Buy) stock ...

SAN FRANCISCO, Oct. 10, 2024 /PRNewswire/ -- The Spoonful of Laughter campaign is a national initiative using comedy to educate about diabetes, counter harmful stereotypes and stigma, and amplify authentic, respectful, and empowering representations of people living with diabetes. The campaign is from the diaTribe Foundation, a nonprofit dedicated to diabetes education and advocacy, and a leader in the movement to end diabetes stigma. The Spoonful of Laughter campaign is a national initiative using comedy t ...

Insulet Corp.'s (PODD) recent FDA approval of Omnipod 5 for type 2 diabetes patients is set to expand the product's market potential. The planned launch of Omnipod 5 with Abbott's Freestyle Libre 2 Plus sensor is likely to drive further growth in the U.S. markets. Robust financial strength also bodes well for the stock. However, the rising economic uncertainty and competitive pressures remain concerns for the company. In the past year, this Zacks Rank #3 (Hold) stock has rallied 7.6% compared with the 15.5% ...

UKRAINE - 2021/06/11: In this photo illustration an Insulet Corporation logo is seen on a smartphone ... [+] and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over this period. The two stocks that focus on the glucose monitoring ...

The company had encouraging news to impart about its leading insulin pump. Specialty device maker Insulet (PODD 0.36%) had some good news to impart to the world early this week, and investors jumped on the stock as a result. As the market started to prepare for its weekend early Friday, Insulet's share price had risen by almost 11% week to date, according to data compiled by S&P Global Market Intelligence. New approval granted Insulet specializes in insulin pumps, and on Monday it formally announced its lat ...

Insulet Corp.'s (PODD) groundbreaking Omnipod 5 Automated Insulin Delivery ("AID") system (Omnipod 5) received the FDA's approval for use by type 2 diabetes patients (ages 18 years and above). The news comes after the company submitted 510(k) for an expanded indication of Omnipod 5 to the FDA, in June 2024, based on the favorable clinical outcomes of the SECURE-T2D pivotal trial. With this development, Omnipod 5 is the first and only AID system indicated for both type 1 and type 2 diabetes. Insulet's Robust ...

Key Takeaways Shares of Insulet and DexCom, which provide devices for patients with diabetes, were the weakestperforming S&P 500 stocks on Tuesday. The losses for the medtech stocks came after Eli Lilly said its blockbuster drug effectively reduced the risk of patients developing type 2 diabetes. Insulet and DexCom have been navigating headwinds related to their user growth outlook. Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled ...

文章核心观点 - 公司的Omnipod设备销售强劲,帮助公司超越了第二季度营收预期 [3] - 公司提高了全年营收增长指引 [8] - 公司预计下半年新用户增长可能低于此前预期,主要是由于从竞争设备转换的患者数量减少 [5] 公司表现 - 公司第二季度实现每股摊薄收益2.59美元,营收4.885亿美元,同比增长 [3] - Omnipod设备销售同比增长26.3% [3] - 调整后每股收益0.55美元略低于预期,因公司确认了1350万美元的存货未利用成本 [4] 投资评级和目标价 - 分析师维持"跑赢大盘"评级,目标价238美元,认为公司利润率提升和全球销售增长潜力可观 [7] - 公司股价自年初以来下跌约16% [8]